Search Results
Your search for ASCO Post,ASCO Post matches 17749 pages
Showing 51 - 100Real-World Study Highlights Gaps in Hypomethylating Agent Treatment for MDS
Researchers have identified age-, sex-, and race-related disparities around treatment with hypomethylating agents for patients with myelodysplastic syndromes in the United States. The receipt of hypomethylating agents was found to favor younger, male, White patients, according to findings published ...
Protease Activator Approved by the FDA for Diffuse Midline Glioma
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to dordaviprone (Modeyso) a protease activator, for adult and pediatric patients aged 1 year and older with diffuse midline glioma harboring an H3 K27M mutation who have progressive disease after prior therapy. This...
RCC: Genetic Testing Key to Avoiding Misdiagnosis of Rare Subtypes
Genetic testing may be the only way to differentiate between common and more rare subtypes of renal cell carcinoma (RCC) to prevent misdiagnoses, according to the results of a study published in Human Pathology. Mucinous tubular and spindle cell carcinoma (MTSCC) was found to share many...
Advancing Geriatric Oncology: Where We Have Been and Where We Are Going
The aging population is rapidly growing, with the number of older adults rising steadily each year. In the 1980s, experts predicted a rise in the number of older patients with cancer, yet we were unprepared. The shortage of oncologists, along with many experienced clinicians retiring early, has...
ASCO Edge Launches for All Members
ASCO has announced the launch of ASCO Edge, an online oncology practice and operations management educational series developed by oncology professionals for oncology professionals. ASCO Edge is a member-only benefit that will provide ASCO members with education and tools to effectively manage the...
Immunoglobulin Replacement Therapy and Infection Risks in CLL
Immunoglobulin replacement therapy did not lead to a reduction in the risk for serious infections leading to hospitalizations for patients with chronic lymphocytic leukemia (CLL), according to the results of a real-world Australian cohort study published in Blood Advances. This finding is at odds...
Perceived Dermatologic Side Effects of Cancer Treatment: Pilot Survey Findings
A recent study published by Menta et al in the Journal of Drugs in Dermatology found that many people misunderstand how common skin, hair, and nail side effects are during cancer treatment—and those fears may lead some to avoid or delay care. Conducted by researchers at the George Washington...
Pediatric Gliomas: Early Research on Targeted Therapies
A collaborative study between Dana-Farber Cancer Institute and the Broad Institute found that 8.9% of children with glioma, the most common type of pediatric brain tumor, have alterations in the fibroblast growth factor receptor (FGFR) family of proteins, and these gliomas may be sensitive to...
Ultraprocessed Food Consumption May Be Linked to Increased Lung Cancer Risk
Greater consumption of ultraprocessed food is associated with an increased risk of developing either small cell or non–small cell lung cancer, according to findings published in Thorax. "Over the past 2 decades, the consumption of ultraprocessed food has significantly increased worldwide,...
Prostate Cancer: One in Six Grade Group 1 Cases Linked to Higher-Risk Disease
Patients classified with "grade group 1" prostate cancer face a wide range of long-term outcomes, according to findings from a study published in JAMA Oncology. Investigators revealed that as many as one in six men with grade group 1 prostate cancers have intermediate- or high-risk disease when...
Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma
The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could reduce recurrence after definitive local therapy for patients who had high-risk features....
Clinical Utility of Including ctDNA Monitoring in Standard-of-Care CRC Surveillance
Arvind N. Dasari, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses data presented at the ESMO Gastrointestinal Cancers Congress 2025, which showed that adding circulating tumor DNA (ctDNA) testing to current standard of care surveillance for patients with colorectal cancer...
MRD Testing: Recent Data and Ongoing Efforts
Circulating tumor DNA has many roles in cancer treatment: early diagnosis, tumor profiling, determining response to therapy, and tracking clinical dynamics. In this video, Arvind N. Dasari, MD, MS, of The University of Texas MD Anderson Cancer Center, focuses on it as a marker for measurable...
Updated CHEST Guidelines Emphasize Minimally Invasive Surgery for Early-Stage NSCLC
Updated clinical guidelines for the management of patients with early-stage non–small cell lung cancer (NSCLC) from the American College of Chest Physicians (CHEST) recommend use of more minimally invasive procedures and methods where possible. The guidelines, published in the journal CHEST,...
LLS Unveils Name Change
The Leukemia & Lymphoma Society (LLS), the global nonprofit in funding blood cancer research, patient support, and advocacy, is becoming Blood Cancer United on August 28, in advance of Blood Cancer Awareness Month in September. For more than 75 years, LLS has been committed to reaching and...
Cannabis Use Disorder and Risk of Oral Cancer
Cannabis use disorder was associated with at least a threefold increase in the risk for developing oral cancer over 5 years compared with those without cannabis use disorder, according to findings from a multicenter clinical cohort analysis published in Preventive Medicine Reports. “Cannabis smoke ...
FIGO Releases Best Practice Advice on Cancer During Pregnancy
The International Federation of Gynecology and Obstetrics (FIGO) has released a best practice guideline addressing cancer in pregnancy, a condition with limited data and complex diagnostic challenges. This new guidance—published by Nanda et al in the International Journal of Gynecology &...
Acute Myeloid Leukemia With RUNX1::RUNX1T1 Fusion
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the impact of the prognostic marker RUNX1::RUX1T1 fusion on the diagnosis and treatment of...
AI Enhances Detection of Missed Breast Cancers on Screening Tomosynthesis
A U.S. Food and Drug Administration (FDA)–cleared artificial intelligence (AI) algorithm was able to detect and correctly localize almost one-third of interval breast cancers in a retrospective evaluation of screening digital breast tomosynthesis (DBT), findings published in Radiology showed. The...
Three in Five Liver Cancer Cases May Be Due to Preventable Risk Factors, The Lancet Commission Finds
Globally, three in five liver cancer cases may be due to preventable risk factors, and obesity-linked cases of the disease are on the rise, according to findings from The Lancet Commission on hepatocellular carcinoma. The majority of liver cancer cases could be prevented by reducing levels of viral ...
STRIDE in Unresectable HCC: 5-Year Overall Survival Results From HIMALAYA
A recent exploratory analysis of the phase III HIMALAYA trial involving patients with unresectable hepatocellular carcinoma (HCC) has shown that 1 in 5 participants (19.6%) treated with the STRIDE regimen (single tremelimumab regular interval durvalumab) remained alive after 5 years of follow-up vs ...
Standard DNA Testing May Miss Majority of NUT Carcinomas, Study Finds
When a NUT carcinoma is detected, standard-of-care DNA next-generation sequencing (NGS) may be unable to detect upward of 75% of incidences of the disease, according to findings published in Clinical Cancer Research. The study authors suggested that to correctly detect and diagnosis NUT carcinomas, ...
Surviving Pancreatic Cancer
I’ve been blessed to have remained healthy for most of my life. In fact, I can’t remember ever spending a night in the hospital until I was diagnosed with pancreatic cancer, at age 86, in the summer of 2024. And even then, the symptoms that drove me to seek care in the emergency room of my local...
Realizing the Full Potential of Patient Engagement in Clinical Research
Nothing about us without us is a centuries-old value that is a cornerstone of meaningful patient engagement in clinical research. Such engagement has not been automatic and is still largely absent in geriatric oncology research, where older patients traditionally have been excluded from clinical...
Patritumab Deruxtecan Shows Efficacy in Leptomeningeal Metastases From Solid Tumors
The HER3-directed antibody-drug conjugate patritumab deruxtecan demonstrated clinical efficacy in treating patients with leptomeningeal metastatic disease of solid tumors, according to findings from a cohort of the phase II TUXEDO-3 trial. Researchers were also encouraged by the intracranial...
Intense Resistance Training for Breast Cancer Survivors With Lymphedema Risk
Resistance training can provide many benefits, including increased muscle mass; decreased adipose tissue; and improved metabolism, bone density, strength, and mobility. However, data are limited on the association between resistance training and the development or exacerbation of lymphedema, a...
ASTRO Announces New President-Elect, Officers
The members of the American Society for Radiation Oncology (ASTRO) recently elected four new officers to ASTRO’s Board of Directors: Catheryn M. Yashar, MD, FASTRO, President-Elect Jonathan Strauss, MD, MBA, Secretary/Treasurer-Elect Anita Mahajan, MD, FASTRO, Health Policy Council Vice Chair...
Plenary Highlights Across Tumor Types Reflect Advances in Research, Improvements in Care, and Changes in Practice
The 2025 ASCO Annual Meeting included the presentation of data from more than 7,000 abstracts and clinical trials set to advance research, uncover findings, and in some cases change the standard of practice across multiple tumor types, moving science forward and improving care for the more than 2...
NSCLC Trial Shows Radiation May Overcome Primary Resistance to Pembrolizumab
The addition of radiation may be able to surmount resistance to immunotherapy for some more immunologically “cold” tumors, as suggested by the findings of a study focused on the immunomodulatory effects of radiation in non–small cell lung cancers (NSCLCs). The research was recently published in...
American Cancer Society Names New CEO
The American Cancer Society (ACS) and its advocacy affiliate the American Cancer Society Cancer Action Network (ACS CAN) have announced Shane Jacobson as their Chief Executive Officer, effective August 12, 2025. He steps into the role following Wayne A.I. Frederick, MD, MBA, FACS, who has served as ...
Short-Term Hormonal Treatment Offers Early Insight Into Tumor Behavior and Resistance for ER+/HER2+ Breast Cancer
How ER-positive, HER2-positive breast cancer tumors respond to a short course of hormonal treatment may help to determine whether more aggressive treatment options are necessary for each patient or not, according to translational findings published in eBioMedicine. Tumor subtype changes after 2...
Evaluation of Racial Classification Standards in U.S. Cancer Surveillance Systems
Despite multiple federal updates to race data collection standards, researchers have found persistent discrepancies in how cancer incidence and mortality rates are recorded for racial minorities—particularly multiracial individuals. A recent study in Cancer highlights how evolving definitions of...
Final Overall Survival Analysis of FLAURA2: Osimertinib Plus Chemotherapy in EGFR-Mutant NSCLC
Positive results from the final overall survival analysis of the phase III FLAURA2 trial showed that osimertinib (a third-generation, irreversible EGFR tyrosine kinase inhibitor) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically...
CBO Report Finds Federal Cuts to NIH Would Threaten New Drug Development and Innovation
A new report from the nonpartisan Congressional Budget Office (CBO) has found that proposed cuts at the National Institutes of Health (NIH) could lower the number of new drugs that come to market in the next 3 decades. The report comes as Congress considers President Trump’s proposed budget for...
Study Finds No Difference in Dietary Habits Between Cancer Survivors and General Population
Researchers have discovered that most cancer survivors do not make significant improvements to their diet or eating habits after their cancer diagnosis, according to findings published in Public Health Nutrition. Despite their cancer diagnosis, there was no significant difference in diet-related...
Real-World Data Show COVID-19 Boosters Offer Protection for Patients With Cancer
COVID-19 vaccine boosters for adult patients with cancer helped to keep these patients from being hospitalized or admitted to intensive care units due to severe COVID-19 infections, according to the results of a retrospective cohort study published in JAMA Oncology. “Cancer patients are a...
Outcomes Support CAR T-Cell Therapy Use in Elderly Patients With B-Cell Lymphomas
Patients in their 80s or older with B-cell lymphomas are able to receive chimeric antigen receptor (CAR) T-cell therapy safely, results of a multicenter retrospective study published in Bone Marrow Transplantation showed. These patients are usually not eligible for clinical trials of CAR T-cell...
Classifying Pancreatic Cysts Using AI Models
In a proof-of-concept study published in the Journal of the American College of Surgeons, researchers investigated whether artificial intelligence (AI) models such as ChatGPT-4 can be used to accurately extract and classify diagnostic data from radiologic imaging reports of pancreatic cysts. The...
Study Links Childhood Proximity to Radiation-Contaminated Coldwater Creek With Elevated Cancer Odds
Living near Coldwater Creek in St. Louis, Missouri, during childhood was found to be associated with an increased risk of overall cancer, according to the findings of a study published in JAMA Network Open. “Our research indicates that the communities around North St. Louis appear to have had...
Survey Highlights Top Anxiety Points for Caregivers After a Cancer Diagnosis
New survey findings highlight that the anxiety caused by a cancer diagnosis extends far beyond just the patient diagnosed. The emotional impact is shared by caregivers and loved ones, with stress, grief, and worry over treatments, pain, and life expectancy weighing heavily on these individuals,...
Can Use of Aprepitant During Chemotherapy Improve Triple-Negative Breast Cancer Outcomes?
Aprepitant, a commonly used antiemetic, led to improvements in patient outcomes when given during chemotherapy treatment for patients with non-luminal early breast cancer. Patients showed better prognoses and survival advantages, particularly among those with triple-negative breast cancer. Study...
Online AI Tool Offers Rapid, Accurate Diagnosis for Endocrine Cancers
Researchers have developed a novel AI-powered online platform for diagnosing endocrine cancers with speed and accuracy. The AI models achieved diagnostic accuracy of 99% or more in recognizing multiple endocrine tumors. Reports of the development and validation of the models were presented at ENDO...
People With Acromegaly Face Elevated Cancer Risk, Study Finds
A new study presented at the 2025 Annual Meeting of the Endocrine Society (ENDO 2025) found that individuals with acromegaly—an endocrine disorder caused by excessive growth hormone secretion—are at a significantly heightened risk of developing various types of cancer, often at younger ages...
New Guidelines on Comprehensive Biomarker Testing of Bronchoscopic Biopsies
Linear endobronchial guided sampling of accessible mediastinal lesions is well established as a first-choice modality for lung cancer mediastinal staging. Parenchymal lung lesions, however, are routinely accessed by either a percutaneous (CT-guided) or a bronchoscopic approach. There have been few...
Phase II Trial Supports SRT as Alternative to WBRT in SCLC
Patients with small cell lung cancer (SCLC) that has metastasized to the brain were safely and successfully treated with targeted stereotactic radiation (SRT) rather than whole-brain radiation therapy (WBRT) in a phase II trial, demonstrating the practicality of a less-invasive approach for...
Four-Year Outcomes Highlight Efficacy of Neoadjuvant Nivolumab and Relatlimab in Advanced Resectable Melanoma
A neoadjuvant and adjuvant regimen of anti–PD-1 therapy with nivolumab and anti–LAG-3 therapy with relatlimab led to a 4-year event-free survival rate of 80% in patients with advanced, resectable melanoma, according to long-term findings from a phase II study published in the Journal of Clinical...
New Research Offers Reassurance About Localized Prostate Cancer Prognosis
A recent study out of Sweden found that people diagnosed with nonmetastatic low-risk prostate cancer later in life were 90% more likely to survive their cancer for their remaining life expectancy if they were treated according to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Of...
Chemoimmunotherapy for Advanced BTC: 3-Year Overall Survival Update From the TOPAZ Trial
In a follow-up analysis of the pivotal TOPAZ-1 study, which established the combination of the PD-L1 inhibitor durvalumab plus gemcitabine and cisplatin as the first-line treatment for advanced biliary tract cancer (BTC), researchers have shown that after 3 years, more than twice as many study...
RP1 Plus Nivolumab in Anti–PD-1–Resistant Advanced Melanoma
When combined with nivolumab, RP1 (vusolimogene oderparepvec), a genetically engineered herpes simplex virus type 1–based oncolytic immunotherapy, induced deep and durable systemic responses in patients with advanced melanoma who have failed to respond to prior anti–PD-1 therapy, according to...
Literature Review Highlights Rising Incidence and Disparities in Many Early-Onset GI Cancers
Rates of early-onset gastrointestinal cancers, beyond just colorectal cancer, are rising among people younger than age 50, according to experts from Dana-Farber Cancer Institute. Researchers from Dana-Farber published a literature review in the British Journal of Surgery showing that cases of newly ...
